RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR t therapy targets BAFFR to fight Hard-to-Treat leukemia
Disease control OngoingThis early-phase study tests a new type of CAR T cell therapy that targets a protein called BAFFR on leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to at least two prior treatments. The main goal is to check safety an…
Matched conditions: RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Engineered immune cells take on relapsed leukemia in new trial
Disease control OngoingThis study tests a treatment called AUTO1, which uses a patient's own immune cells (T cells) that are modified in a lab to find and attack cancer cells. It is for adults with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or not responded to stand…
Matched conditions: RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Autolus Limited • Aim: Disease control
Last updated May 13, 2026 16:03 UTC